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Abstract
Following an application from Laboratoires Nutrition et Cardiometabolisme, submitted for authorisation
of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent
Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to Stablor® and decrease in
visceral fat while preserving lean mass. The food Stablor®, a drink preparation with deﬁned macro- and
micronutrient composition and a speciﬁc proportion of amino acids (tryptophan to neutral amino acids
ratio) which is the subject of the health claim, is sufﬁciently characterised. The Panel considers that
reduction of visceral fat while maintaining lean body mass in the context of an energy restricted diet is a
beneﬁcial physiological effect in overweight or obese subjects with abdominal fat and cardiometabolic
risk factors. Four human studies were submitted by the applicant as pertinent to the claimed effect. In
weighing the evidence, the Panel took into account that one human study from which conclusions could
be drawn for scientiﬁc substantiation of the claimed effect did not show an effect of Stablor® on visceral
fat mass in the context of an energy restricted diet. The Panel concludes that a cause and effect
relationship has not been established between the consumption of Stablor® and reduction of visceral fat
while maintaining lean body mass in the context of an energy restricted diet.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: Stablor®, visceral fat, lean body mass, health claim
Requestor: Competent Authority of France following an application by Laboratoires Nutrition et
Cardiometabolisme
Question number: EFSA-Q-2016-00319
Correspondence: nda@efsa.europa.eu
EFSA Journal 2017;15(2):4723www.efsa.europa.eu/efsajournal
Panel members: Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina
Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Monika
Neuh€auser-Berthold, Gra_zyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sj€odin,
Martin Stern, Daniel Tome, Dominique Turck, Henk Van Loveren, Marco Vinceti and Peter Willatts.
Acknowledgements: The Panel wishes to thank the members of the Working Group on Claims:
Jean-Louis Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Harry J McArdle,
Yolanda Sanz, Alfonso Siani, Anders Sj€odin, John Joseph Strain, Henk Van Loveren and Peter Willatts
for the preparatory work on this scientiﬁc opinion.
Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies),
Turck D, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI,
Mangelsdorf I, McArdle HJ, Naska A, Neuh€auser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Sj€odin A,
Stern M, Tome D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain JJ and Siani A, 2017. Scientiﬁc
Opinion on the Stablor® and reduction of visceral fat while maintaining lean mass: evaluation of a
health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2017;15
(2):4723, 11 pp. doi:10.2903/j.efsa.2017.4723
ISSN: 1831-4732
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modiﬁcations or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Stablor® and reduction of visceral fat while maintaining lean mass
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2017;15(2):4723
Summary
Following an application from Laboratoires Nutrition et Cardiometabolisme, submitted for
authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was
asked to deliver an opinion on the scientiﬁc substantiation of a health claim related to Stablor® and
reduction of visceral fat while maintaining lean mass in overweight or obese subjects with abdominal
fat and cardiometabolic risk factors.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence. The application included a request for the protection of proprietary data.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientiﬁc requirements for health claims related to appetite ratings, weight management and blood
glucose concentrations.
The food that is the subject of the health claim is Stablor®. The Panel considers that Stablor®, a
drink preparation with deﬁned macro- and micronutrient composition and speciﬁc proportion of amino
acids (tryptophan to neutral amino acids ratio), is sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘decrease in visceral fat while preserving lean mass’.
The target population proposed by the applicant is ‘overweight or obese subjects with abdominal fat
and cardiometabolic risk factors’. The Panel considers that reduction of visceral fat while maintaining
lean body mass in the context of an energy restricted diet is a beneﬁcial physiological effect in the
target population.
Four human studies were considered by the applicant as pertinent to the claimed effect. The
Panel considers that no conclusions can be drawn from three uncontrolled studies for the scientiﬁc
evaluation of the claim.
The Panel notes that one human intervention study does not show an effect of Stablor® on the
primary outcome (reduction of visceral fat) in the primary (full analysis set (FAS)) analysis and that the
per protocol (PP) analysis for the primary outcome is at risk of bias.
In the absence of evidence for an effect of Stablor® on reduction of visceral fat while maintaining
lean body mass in efﬁcacy studies in humans, the studies on the proposed mechanisms of action were
not considered by the Panel for the scientiﬁc substantiation of the claim.
In weighing the evidence, the Panel took into account that one human study from which
conclusions could be drawn for scientiﬁc substantiation of the claimed effect did not show an effect of
Stablor® on reduction of visceral fat while maintaining lean body mass in the context of an energy
restricted diet.
On the basis of data presented, the Panel concludes that a cause and effect relationship has not
been established between the consumption of Stablor® and reduction of visceral fat while maintaining
lean body mass in the context of an energy restricted diet.
Stablor® and reduction of visceral fat while maintaining lean mass
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: Stablor® and decrease in visceral
fat while maintaining lean mass in overweight or obese subjects with abdominal fat and
cardiometabolic risk factors.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of Stablor®, a positive assessment of its safety, nor a decision on whether Stablor® is, or is
not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is Stablor®, a drink
preparation containing a protein fraction with a speciﬁc proportion of amino acids, a patented ratio
between tryptophan (Trp) and neutral amino acids (NAAs) as well as particular vitamin and mineral
fractions. This preparation has to be mixed with water before consumption.
Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to: ‘a decrease visceral fat while preserving
lean mass in overweight or obese subjects with abdominal fat and cardiometabolic risk factors’, in the
context of a well-balanced diet and a mild caloric restriction, to which the food is added.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
According to the applicant, Stablor® works to counteract and normalise different metabolic
disorders linked to excessive visceral fat, particularly dysregulation of the Trp metabolism and
disturbances in the protein metabolism. The consumption of Stablor® also ensures a better balance of
micronutrients intake in subjects that are known to have deﬁciencies. Stablor® has also potential
action on microbiome modulation and intestinal epithelial barrier.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘In the context of a
well-balanced diet and a mild caloric restriction, the addition of Stablor® contributes to decrease
visceral fat while preserving lean mass in overweight or obese subjects with abdominal fat and
cardiometabolic risk factors’.
Speciﬁc conditions of use as proposed by the applicant
According to the applicant, Stablor® has to be mixed with water before consumption as a drink.
The applicant advises to consume two sachets of Stablor® daily in the framework of a diet
containing 50% carbohydrates, 35% fats and 15% proteins, with a low glycaemic load, together with
a mild caloric restriction (600 kcal/day) leading to a total daily intake of 1,750 kcal/day on average.
Data provided by the applicant
Health claim application on consumption of Stablor® and reduction of visceral fat while maintaining
lean mass in overweight or obese subjects with abdominal adiposity and cardiometabolic risk factors
pursuant to Article 13.5 of Regulation 1924/2006, presented in a common and structured format as
outlined in the Scientiﬁc and technical guidance for the preparation and presentation of applications for
authorisation of health claims (EFSA NDA Panel, 2017).
As outlined in the General guidance for stakeholders on health claim applications (EFSA NDA Panel,
2016), it is the responsibility of the applicant to provide the totality of the available evidence.
This health claim application includes a request for the protection of proprietary data in accordance
with Article 21 of Regulation (EC) No 1924/2006. Data claimed to be proprietary and conﬁdential by
the applicant include:
• the manufacturing process of the ﬁnished product;
• the manufacturing formula of the food. However, the information that calcium caseinate,
wheat protein and mixed minerals and vitamins are used needs to be disclosed as this is
essential information in relation to the claim;
• the detailed speciﬁcations of the food, including analytical methods used to ensure the quality
of the product. However, information related to macronutrients content, caloric value of the
product, vitamins and minerals content needs to be disclosed as this is essential information in
relation to the claim;
• the clinical report of the unpublished human study (Clement and La Marche, 2014; –
unpublished report) and of its ancillary study (Genoscreen Report, 2015 – unpublished report)
However, information related to macronutrients content, caloric value of the product, vitamins
and minerals content needs to be disclosed as this is essential information in relation to the
claim. The detailed information related to comparator composition will be not disclosed.
However, information related to macronutrients content and caloric value of the comparator
needs to be disclosed as this is essential information in relation to the claim.
Methodologies
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to appetite ratings, weight management, and
blood glucose concentrations are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2012).
3. Assessment
3.1. Characterisation of the food/constituent
The food that is proposed by the applicant as the subject of the health claim is Stablor®, a drink
preparation containing a protein fraction with a speciﬁc proportion of amino acids (ratio between Trp
and NAAs) and a ﬁxed combination of vitamins and minerals. The preparation is offered in sachets and
needs to be dissolved in around 200 mL of water before consumption. Three ﬂavours are available:
chocolate, coffee and vanilla-toffee.
The composition of three ﬂavours of Stablor® has been provided. The list of ingredients is as
follows: calcium caseinate, whey protein concentrate, whey protein hydrolysate, whey protein isolate,
free amino acids mix (Gln, Leu, Arg, Trp and taurine), milk minerals concentrate, vitamins (B6, folic
Stablor® and reduction of visceral fat while maintaining lean mass
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acid, E and D), minerals (zinc gluconate, chromium chloride, trimagnesium citrate, potassium
phosphate and acesulfame potassium) and soluble chicory ﬁbres. The amounts of each of these
components per 100 g, per sachet and per recommended dose (two sachets) have been provided.
The manufacturing process is claimed by the applicant as conﬁdential.
The macronutrient composition of the ﬁnished product for each of the three ﬂavours has
been provided. The content of protein, carbohydrate, fat and ﬁbre are 62.5–63.0 g/100 g,
8.5–13.0 g/100 g, 2.7–4.7 g/100 g and 6.9–9.1 g/100 g, respectively, depending on the ﬂavour.
Technical datasheets for all the ingredients and speciﬁcations for the ﬁnished products are provided,
along with reference methods for testing the components (including microbiological analyses).
Information related to stability and batch-to-batch variability was provided.
The Panel considers that the food Stablor®, a drink preparation with deﬁned macro- and
micronutrient composition and speciﬁc proportion of amino acids (tryptophan to neutral amino acids
ratio), which is the subject of the health claim, is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘decrease in visceral fat while preserving lean mass’.
The target population proposed by the applicant is ‘overweight or obese subjects with abdominal fat
and cardiometabolic risk factors’.
The scientiﬁc evidence for the substantiation of health claims related to the reduction of abdominal
fat can be obtained from human intervention studies showing a reduction in abdominal fat by using
methods with appropriate validity and precision (e.g. magnetic resonance imaging (MRI) and
computed tomography (CT)). Surrogate measures of abdominal fat (e.g. waist circumference) could be
used for the scientiﬁc substantiation of these claims if the reduction is sufﬁciently large so that it could
not be attributed to a reduction in lean body mass/body water. The conditions in which the effect is
achieved need to be speciﬁed (under energy-restriction, eating ad libitum, etc.). Evidence for a
sustained effect with continuous consumption of the food/constituent over, for example, about
12 weeks, should also be provided (EFSA NDA Panel, 2012).
The scientiﬁc evidence for the substantiation of health claims on the increase/maintenance of lean
body mass can be obtained from human intervention studies showing an increase (or reduced loss) in
lean body mass which could not be attributed to an increase in body weight (i.e. an increase in lean
body mass relative to body fat mass). Changes in lean body mass should be assessed using methods
with appropriate validity and precision. Imaging techniques (e.g. dual energy x-ray absorptiometry
(DXA), MRI and CT) are generally appropriate to assess changes in lean body mass in human
intervention studies. Bioimpedance analysis (BIA) and air-displacement plethysmography (ADP) may
not be appropriate to assess small changes in lean body mass when used alone, particularly in obese
subjects and/or when signiﬁcant changes in body water compartments occur. The conditions in which
the effect is achieved need to be speciﬁed (e.g. training vs usual physical activity, eating ad libitum vs
energy-restriction, etc.). Evidence for a sustained effect with continuous consumption of the food/
constituent over, for example, about 12 weeks, should also be provided. Measurements of protein
metabolism (e.g. synthesis and breakdown) may be used in support of a mechanism by which the
food/constituent could exert the claimed effect (EFSA NDA Panel, 2012).
The Panel considers that reduction of visceral fat while maintaining lean body mass in the context
of an energy restricted diet is a beneﬁcial physiological effect in the target population.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in the PubMed, Science Direct and Google scholar
databases using the following search terms: ‘Stablor’ AND (obese OR obesity OR weight OR waist OR
abdominal fat OR lean mass). Papers published in English or French were selected. Additional hand
searching was also performed.
Human studies
Four human studies (two published and two unpublished) were considered by the applicant as
pertinent to the claim.
Three studies (Ranson, 2013, 2014; UCP Abridged Report, 2014, unpublished study report)
investigated the effect of Stablor® on body weight and visceral fat-related outcomes in the context of an
energy-restricted diet, but the lack of a control group does not allow conclusions on the effect of
Stablor® and reduction of visceral fat while maintaining lean mass
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Stablor® per se (i.e. independently of energy restriction) on the outcome variables. The Panel considers
that no conclusions can be drawn from these studies for the scientiﬁc substantiation of the claim.
In a randomised, multicentre (two centres) two-arm, double-blind, parallel, controlled study,
Clement and La Marche (2014) evaluated the effect of Stablor® on changes in visceral fat mass and
other cardiometabolic risk factors in overweight and obese subjects meeting the criteria for metabolic
syndrome according to International Diabetes Federation (IDF) standards for a European population.
The Panel considers that the study group (overweight and obese subjects with metabolic
syndrome) is appropriate for a health claim on the reduction of visceral fat.
The study was performed in France (n = 54) and Canada (n = 53). A block randomisation was used
taking into account study centre and gender (desired ratio male/female of 2/3). The participants were
allocated to consume Stablor® (two sachets per day dissolved in water; n = 58) or a ‘comparator’
(n = 59) with the same appearance, ﬂavour and similar energy content (control) for 16 weeks.
The Panel notes that subjects were independently randomised in the two centres with a similar
number of subjects, gender distribution and treatment allocation in the two centres.
The study consisted of a screening period of 3 days to 4 weeks, followed by an intervention period
of 12 weeks with an energy-restricted diet followed by a 4-week maintenance period. From the
inclusion visit, all subjects were advised to follow a standardised energy-restricted diet for 12 weeks.
The target daily energy intake was calculated for each individual as the resting energy expenditure
(REE) 9 1.3 for the physical activity level (PAL) minus 600 kcal (energy deﬁcit). REE was calculated
according to Harris and Benedict equation. The target macronutrient composition of the background
diet was 50%E (energy) as carbohydrates, 35%E as fats and 15%E as proteins. For the next 4 weeks
(weeks 13–16), a stabilisation diet with 20% more energy was prescribed. Dietary advice was given at
the inclusion visit, and after 6, 12 and 16 weeks. A phone call initiated by the dietician was also
performed weekly. Subjects were also instructed to maintain their habitual physical activity level.
Sample size calculation was based on the expected difference in change in the visceral fat area
between the two study groups using one-sided Student t-test, with an estimated difference of 6 cm2
between the two study groups, a common standard deviation of 9 cm2, a ﬁrst one-sided risk alpha of
2.5% and a 90% power. This calculation was based on the assumption that the mean visceral fat
surface would be 150 cm2 at baseline for both groups and will be reduced by 20% (30 cm2) in the
study group and by 16% (24 cm2) in the comparator group. The estimated number of subjects
required per group was 49. A total of 120 subjects were planned to be enrolled, assuming a 20%
dropout rate.
The primary outcome of the study was the absolute change in abdominal visceral fat mass
assessed by computed tomography (CT) in the full analysis set (FAS) population. Upon a request from
EFSA, the applicant speciﬁed that the horizontal slide of the CT scan used to assess abdominal visceral
fat mass was located 5 cm above the L4–L5 intervertebral disc, and that analysis of the scans was
performed centrally by one group of radiologists with the use of automatic calculation of total fat area,
visceral fat area and subcutaneous fat area, for both study sites.
Secondary outcomes were absolute changes in total fat mass, subcutaneous fat mass, visceral
fat/subcutaneous fat ratio, visceral fat/body mass index (BMI) ratio, lean body mass, lean body
mass/fat body mass ratio, blood pressure, waist circumference, glycaemic and lipid proﬁles, amino
acids levels, and C-reactive protein (CRP).
Total body mass, fat mass and lean mass were assessed by DXA following the same procedure in
both centres, although a different software was used in each centre. Upon a request from EFSA, the
applicant clariﬁed that the different versions of the software did not affect the measurement.
The energy content and macronutrient composition of the comparator used in the study was
190–197 kcal per sachet, 15%E as proteins, 49%E as carbohydrates, and 36%E as fats. The applicant
claims that the main differences between Stablor® and the comparator were related to the aminogram
(Trp/NAA ratio, the glutamic acid content and the leucine content).
The Panel notes that the protein content was > 4-fold higher in the Stablor® products
(62.5–63.0 g/100 g) than in the comparator (15.2–15.3 g/100 g). After a request from EFSA to justify
the appropriateness of the macronutrient composition of the comparator to test the effect of Stablor®
on the primary outcome, the applicant argued that the comparator had to be ‘isocaloric to Stablor®
but comply with the macronutrient composition of the background diet (carbohydrate/fat/protein
providing 50%, 35% and 15% of total energy)’.
In the statistical analysis of the results, multiple ANOVA models were used to compare absolute
changes in visceral fat mass between the two groups adjusted for centre, age (in classes) and gender.
The same analyses were conducted for the secondary outcome variables.
Stablor® and reduction of visceral fat while maintaining lean mass
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Upon a request from EFSA, the applicant clariﬁed that corrections for multiple testing were not
used in relation to the statistical analysis of the secondary outcomes.
Upon a request from EFSA, the applicant submitted a Reporting and Analysis Plan (RAP) describing
the planned statistical analyses. The Panel notes that version 1.0 of RAP was dated 31 March 2014
while the study was ﬁnished on 21 February 2014, meaning that this document was not prepared a
priori. The applicant argues, however, that the study was unblinded only after the completion of
the RAP.
While 376 subjects were screened for inclusion, 118 subjects were recruited (59 in each group,
mean age 47.9 years, mean BMI 32.3 kg/m2, 44 men). The FAS was deﬁned by the applicant as all
subjects randomised who consumed at least one sachet of the study product and had one post-
baseline CT scan (54 in the Stablor® group and 53 in comparator group). The per protocol (PP)
analysis was based on all subjects in the FAS population who completed the study without any major
protocol violation (49 in the treatment and 50 in the control group).
Reasons for major protocol violation were poor compliance (< 80%; two subjects on each group),
inclusion criteria not met (two subjects in the Stablor® group and one in the comparator group), and
ingestion of drugs listed in the exclusion criteria (one subject in Stablor® group). Upon a request from
EFSA, the applicant clariﬁed that three subjects who did not meet the inclusion criteria were incorrectly
randomised and that this deviation was detected after completion of the study.
The absolute decrease in visceral fat area was signiﬁcantly higher in the Stablor® group than in the
comparator group in the PP analysis (–20.46  23.14 cm2 vs –12.56  20.77 cm2, p = 0.02), but not
in the FAS (primary) analysis (–20.75  23.24 cm2 vs –14.55  24.30 cm2, p = 0.06).
Upon a request to discuss the observed differences between the FAS and PP analysis, the applicant
explained that in the Stablor® group, ‘the exclusion of ﬁve patients resulted in a –0.29 cm2 (–1.4%)
decrease of the area of visceral fat and a decrease of the variance of –10.5 cm2 (0.5%) while in the
comparator group the exclusion of three patients resulted in a –1.98 cm2 (–13.7%) decrease of the mean
of and a decrease of the variance of –3.53 cm2 (–14.5%)0. The Panel notes that the exclusion of ﬁve
subjects in the Stablor® group and of three subjects in the comparator groups from the FAS to the PP
analysis resulted in an increased difference in fat loss between the groups, mainly due to a smaller
decrease in visceral fat in the comparator group. The SD of the means also decreased accordingly. The
mean decrease in visceral fat area in three subjects excluded from the comparator group was 47.7 cm2,
about 3.8-fold higher than the mean change observed in the remaining subjects (n = 50) in the
comparator group. The Panel notes that the exclusion of the three non-compliant subjects from the
analysis had a big impact on the results, particularly by decreasing the amount of visceral fat mass loss in
the control group. The Panel considers that this study does not show an effect of Stablor® on the primary
outcome in the primary (FAS) analysis and that the PP analysis for the primary outcome is at risk of bias.
The total fat area (measured by CT) signiﬁcantly decreased in the Stablor® group vs the
comparator group in the FAS (–46.64  43.77 cm2 vs –30.85  48.31 cm2, p = 0.023) and PP analysis
(–44.62  43.43 cm2 vs –28.97  43.42 cm2, p = 0.016). No signiﬁcant differences between groups
were reported for other secondary outcomes, including changes in lean body mass, fat mass, blood
pressure, glycaemic and lipid proﬁles, and CRP.
The Panel considers that this study does not show an effect of Stablor® on visceral fat mass in the
context of an energy restricted diet.
Mechanism by which the food/constituent could exert the claimed effect
The applicant indicated several mechanisms by which the Stablor® product could exert the claimed
effect on visceral fat mass while retaining lean body mass, including: (a) regulation of tryptophan
metabolism, (b) regulation of protein metabolism, (c) correction of micronutrient deﬁciencies, (d)
improving the gut barrier dysfunction.
In the absence of evidence for an effect of Stablor® on the reduction of visceral fat mass while
maintaining lean body mass in efﬁcacy studies in humans, the studies provided by the applicant on the
proposed mechanisms by which Stablor® could exert the claimed effect were not considered by the
Panel for the scientiﬁc substantiation of the claim.
Weighing of the evidence
In weighing the evidence, the Panel took into account that one human study from which
conclusions could be drawn for scientiﬁc substantiation of the claimed effect did not show an effect of
Stablor® on visceral fat mass in the context of an energy restricted diet.
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The Panel concludes that a cause and effect relationship has not been established between the
consumption of Stablor® and reduction of visceral fat while maintaining lean body mass in the context
of an energy restricted diet.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, Stablor®, a drink preparation with deﬁned macro- and micronutrient
composition and speciﬁc proportion of amino acids (Trp to NAAs ratio), which is the subject of
the health claim, is sufﬁciently characterised.
• The claimed effect proposed by the applicant is ‘decrease in visceral fat while preserving lean
mass’. The target population proposed by the applicant is ‘overweight or obese subjects with
abdominal fat and cardiometabolic risk factors’. Reduction of visceral fat while maintaining lean
body mass in the context of an energy restricted diet is a beneﬁcial physiological effect in the
target population.
• A cause and effect relationship has not been established between the consumption of Stablor®
and reduction of visceral fat while maintaining lean body mass in the context of an energy
restricted diet.
Steps taken by EFSA
Health claim application on ‘Stablor®’ and ‘reduction of visceral fat while maintaining lean mass’
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 000319_0448_FR).
Submitted by Laboratoires Nutrition et Cardiometabolisme, 38 Cours Clemenceau, 33000 Bordeaux,
France. This application was received by EFSA on 27/4/2016.
1) The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence. The application included a request for the protection of
proprietary data.
2) The scientiﬁc evaluation procedure started on 20/7/2016.
3) On 6/9/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 29/9/2016 and was restarted on 13/10/2016, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
4) On 13/10/2016, EFSA received the applicant’s reply (which was made available to EFSA in
electronic format on 13/10/2016).
5) On 16/11/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 22/12/2016 and was restarted on 6/1/2017, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
6) On 6/1/2017, EFSA received the applicant’s reply (which was made available to EFSA in
electronic format on 6/1/2017).
During its meeting on 31/1/2017, the NDA Panel, having evaluated the data, adopted an opinion on
the scientiﬁc substantiation of a health claim related to Stablor® and reduction of visceral fat while
maintenance of lean body mass.
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Abbreviations
ADP air-displacement plethysmography
ANOVA analysis of variance
BIA bioimpedance Analysis
BMI body mass Index
CRP C-reactive Protein
CT computed tomography
DXA dual energy X-ray absorptiometry
E energy
FAS full analysis set
IDF International Diabetes Federation
NAA neutral amino acids
MRI magnetic resonance imaging
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
PAL physical activity level
PP per protocol
RAP Reporting and Analysis Plan
REE Resting Energy Expenditure
SD standard deviation
Trp tryptophan
Stablor® and reduction of visceral fat while maintaining lean mass
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2017;15(2):4723
